Adapted from IUSG and SUN classifications (56) Anatomical Primary site of Examples classification inflammation of uveitis Anterior Anterior chamber Iritis Iridocyclitis uveitis Iris and ciliary body Intermediate Vitreous Pars plana Pars planitis uveitis Peripheral retina Posterior Fundus posterior to Retinitis Choroiditis uveitis the vitreous face Vasculitis Retina Choroid Neuroretinitis Optic disc
Panuveitis Entire uveal tract and retina Table 2 Clinical classification of uveitis.
Our patient had bilateral
panuveitis and serous retinal detachment with no history of ocular trauma.
Panuveitis, also referred to as diffuse, can encompass anterior, intermediate, and posterior segments.
Patients who had vitritis with retinitis and/or vasculitis were classified as having posterior uveitis, and those who had anterior and posterior uveitis at the same time were classified as having
panuveitis.
Abstracts to be presented include data from a Phase 3 pivotal trial evaluating the efficacy and safety of HUMIRA as an investigational treatment for patients with non-infectious intermediate, posterior, or
panuveitis, insights into the real-world impact of rheumatologic diseases, and new research on AbbVie's investigational medicines for rheumatoid arthritis, knee osteoarthritis and lupus.
Inflammation of all three locations is termed
panuveitis.
May 5, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced results from VISUALCaeI, a Phase 3 study investigating the efficacy and safety of HUMIRA (adalimumab) in adult patients with active non-infectious intermediate, posterior, or
panuveitis who still experienced intraocular inflammation while on systemic corticosteroid therapy.
Effect of infliksimab on sight-threatening
panuveitis in Behcet's disease.
LX211 is designed for use as an oral immune-modulatory agent to treat the forms of non-infectious uveitis that require systemic treatment, including posterior, intermediate and
panuveitis, allowing for tapering of systemic corticosteroids to 5 mg or less per day.
LX211 is a next-generation calcineurin inhibitor intended for the treatment of non-infectious posterior, intermediate and
panuveitis (an autoimmune disease characterized by chronic inflammation of the eye).
In another trial of 19 patients with severe endogenous anterior uveitis and
panuveitis (more than 50 anterior chamber cells) that did not respond to previous therapies, Durezol QID was effective in reducing anterior chamber cell, flare, and total sign and symptom scores.
Lux initially plans to develop an oral form of ISA247 as a potential treatment for posterior, intermediate and
panuveitis, a serious and potentially sight-threatening inflammatory disease of the eye.
